We develop Pentarins™, which are novel miniaturized biologic drug conjugates uniquely designed to target, penetrate and treat solid tumors.
Developing novel cancer therapies that address the challenges of effectively treating solid tumors.
Blend creates Pentarins that are targeted miniature drug conjugates that remain miniature by design to overcome the challenges that limit the efficacy of larger antibody drug conjugates in use and in development today. Specifically, our Pentarins are designed to penetrate deep into solid tumors, target cancer cells selectively, drive sufficient accumulation of the drug at the site of the tumor, deliver effective, potent payloads into the targeted cancer cells, and cause cancer cell death deep within the solid tumors.
Blend’s innovative cancer therapies are based on the company’s Pentarin platform, through which we create our novel, miniaturized biologic drug conjugates. With our platform capabilities and cancer drug development expertise, our team creates Pentarins comprised of an innovative targeting ligand, linked to a potent payload, designed to penetrate deep into solid tumors and cause cancer cell death.
Pentarins are engineered to possess tuned pharmacokinetic and biodistribution properties for anti-cancer efficacy, through inherent design or by nanoparticle incorporation. The result is a product platform enabling the development of novel Pentarins with the unprecedented ability to therapeutically penetrate deep into the solid tumor tissue and drive efficacy.
Advancing our proprietary Pentarins through internal development and external collaboration.
Through our Pentarin platform, Blend is developing an internal pipeline of proprietary drug conjugates with tuned properties to improve solid tumor treatment. We are advancing Pentarins directed against a wide set of cell surface and deep tumor targets, as we focus on cancers where there is a significant unmet clinical need that overlaps with our approach to the treatment of solid tumors. Our first Pentarin, PEN-221, is designed for the treatment of patients with neuroendocrine cancers, including small cell lung cancer, that overexpress the somatostatin receptor. PEN-221 is expected to be in the clinic in mid-2016.
Our proprietary platform is applicable to a wide range of solid tumor targets and Blend is broadening our internal pipeline of candidates to address multiple areas of unmet need. Also, in conjunction with pharmaceutical collaborators, our platform can serve as the foundation for developing efficacious Pentarins by leveraging and incorporating proprietary targeting peptide and protein scaffolds or payloads of pharmaceutical companies.
To inquire about Pentarin collaborations, contact us at email@example.com